19 October 2022
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid
28 June 2022
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology
10 May 2022
Domain Therapeutics raises $42m Series A financing
Thank you for your form submission, we will get in contact with you shortly.